These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 32391646

  • 1. Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
    Chan AM, Enwere E, McIntyre JB, Wilson H, Nwaroh C, Wiebe N, Ou Y, Liu S, Wiedemeyer K, Rambau PF, Grevers X, Morris DG, Neri P, Gilks CB, Visser F, Le N, Luo L, Cook LS, Köbel M.
    J Pathol Clin Res; 2020 Oct; 6(4):252-262. PubMed ID: 32391646
    [Abstract] [Full Text] [Related]

  • 2. CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.
    Kang EY, Weir A, Meagher NS, Farrington K, Nelson GS, Ghatage P, Lee CH, Riggan MJ, Bolithon A, Popovic G, Leung B, Tang K, Lambie N, Millstein J, Alsop J, Anglesio MS, Ataseven B, Barlow E, Beckmann MW, Berger J, Bisinotto C, Bösmüller H, Boros J, Brand AH, Brooks-Wilson A, Brucker SY, Carney ME, Casablanca Y, Cazorla-Jiménez A, Cohen PA, Conrads TP, Cook LS, Coulson P, Courtney-Brooks M, Cramer DW, Crowe P, Cunningham JM, Cybulski C, Darcy KM, El-Bahrawy MA, Elishaev E, Erber R, Farrell R, Fereday S, Fischer A, García MJ, Gayther SA, Gentry-Maharaj A, Gilks CB, AOCS GroupCentre for Cancer Research, The Westmead Institute for Medical Research, University of Sydney, Sydney, New South Wales, Australia.Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia., Grube M, Harnett PR, Harrington SP, Harter P, Hartmann A, Hecht JL, Heikaus S, Hein A, Heitz F, Hendley J, Hernandez BY, Polo SH, Heublein S, Hirasawa A, Høgdall E, Høgdall CK, Horlings HM, Huntsman DG, Huzarski T, Jewell A, Jimenez-Linan M, Jones ME, Kaufmann SH, Kennedy CJ, Khabele D, Kommoss FKF, Kruitwagen RFPM, Lambrechts D, Le ND, Lener M, Lester J, Leung Y, Linder A, Loverix L, Lubiński J, Madan R, Maxwell GL, Modugno F, Neuhausen SL, Olawaiye A, Olbrecht S, Orsulic S, Palacios J, Pearce CL, Pike MC, Quinn CM, Mohan GR, Rodríguez-Antona C, Ruebner M, Ryan A, Salfinger SG, Sasamoto N, Schildkraut JM, Schoemaker MJ, Shah M, Sharma R, Shvetsov YB, Singh N, Sonke GS, Steele L, Stewart CJR, Sundfeldt K, Swerdlow AJ, Talhouk A, Tan A, Taylor SE, Terry KL, Tołoczko A, Traficante N, Van de Vijver KK, van der Aa MA, Van Gorp T, Van Nieuwenhuysen E, van-Wagensveld L, Vergote I, Vierkant RA, Wang C, Wilkens LR, Winham SJ, Wu AH, Benitez J, Berchuck A, Candido Dos Reis FJ, DeFazio A, Fasching PA, Goode EL, Goodman MT, Gronwald J, Karlan BY, Kommoss S, Menon U, Sinn HP, Staebler A, Brenton JD, Bowtell DD, Pharoah PDP, Ramus SJ, Köbel M.
    Cancer; 2023 Mar 01; 129(5):697-713. PubMed ID: 36572991
    [Abstract] [Full Text] [Related]

  • 3. PTEN Deficiency in Tubo-Ovarian High-Grade Serous Carcinoma is Associated with Poor Progression-Free Survival and is Mutually Exclusive with CCNE1 Amplification.
    Zhang X, Wang A, Han L, Liang B, Allard G, Diver E, Howitt BE.
    Mod Pathol; 2023 May 01; 36(5):100106. PubMed ID: 36805789
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The gene copy number of c-MET has a significant impact on progression-free survival in Korean patients with ovarian carcinoma.
    Kim WY, Shim SH, Jung HY, Dong M, Kim SN, Lee SJ.
    Hum Pathol; 2017 Jun 01; 64():98-105. PubMed ID: 28428108
    [Abstract] [Full Text] [Related]

  • 8. Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma.
    Howitt BE, Hanamornroongruang S, Lin DI, Conner JE, Schulte S, Horowitz N, Crum CP, Meserve EE.
    Am J Surg Pathol; 2015 Mar 01; 39(3):287-93. PubMed ID: 25581732
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma.
    Saner FAM, Takahashi K, Budden T, Pandey A, Ariyaratne D, Zwimpfer TA, Meagher NS, Fereday S, Twomey L, Pishas KI, Hoang T, Bolithon A, Traficante N, Australian Ovarian Cancer Study Group, Alsop K, Christie EL, Kang EY, Nelson GS, Ghatage P, Lee CH, Riggan MJ, Alsop J, Beckmann MW, Boros J, Brand AH, Brooks-Wilson A, Carney ME, Coulson P, Courtney-Brooks M, Cushing-Haugen KL, Cybulski C, El-Bahrawy MA, Elishaev E, Erber R, Gayther SA, Gentry-Maharaj A, Gilks CB, Harnett PR, Harris HR, Hartmann A, Hein A, Hendley J, Hernandez BY, Jakubowska A, Jimenez-Linan M, Jones ME, Kaufmann SH, Kennedy CJ, Kluz T, Koziak JM, Kristjansdottir B, Le ND, Lener M, Lester J, Lubiński J, Mateoiu C, Orsulic S, Ruebner M, Schoemaker MJ, Shah M, Sharma R, Sherman ME, Shvetsov YB, Soong TR, Steed H, Sukumvanich P, Talhouk A, Taylor SE, Vierkant RA, Wang C, Widschwendter M, Wilkens LR, Winham SJ, Anglesio MS, Berchuck A, Brenton JD, Campbell I, Cook LS, Doherty JA, Fasching PA, Fortner RT, Goodman MT, Gronwald J, Huntsman DG, Karlan BY, Kelemen LE, Menon U, Modugno F, Pharoah PDP, Schildkraut JM, Sundfeldt K, Swerdlow AJ, Goode EL, DeFazio A, Köbel M, Ramus SJ, Bowtell DDL, Garsed DW.
    Clin Cancer Res; 2024 Aug 15; 30(16):3481-3498. PubMed ID: 38837893
    [Abstract] [Full Text] [Related]

  • 14. High cyclin E1 protein, but not gene amplification, is prognostic for basal-like breast cancer.
    Aziz D, Lee C, Chin V, Fernandez KJ, Phan Z, kConFab InvestigatorsPeter MacCallum Cancer Centre, Victorian Comprehensive Cancer Centre, Parkville, VIC, Australia.Sir Peter MacCallum Cancer Centre, Department of Oncology, The University of Melbourne, Parkville, VIC, Australia., AOCS Study GroupPeter MacCallum Cancer Centre, Victorian Comprehensive Cancer Centre, Parkville, VIC, Australia., Waring P, Caldon CE.
    J Pathol Clin Res; 2022 Jul 15; 8(4):355-370. PubMed ID: 35384378
    [Abstract] [Full Text] [Related]

  • 15. Invasion Patterns of Metastatic Extrauterine High-grade Serous Carcinoma With BRCA Germline Mutation and Correlation With Clinical Outcomes.
    Hussein YR, Ducie JA, Arnold AG, Kauff ND, Vargas-Alvarez HA, Sala E, Levine DA, Soslow RA.
    Am J Surg Pathol; 2016 Mar 15; 40(3):404-9. PubMed ID: 26574845
    [Abstract] [Full Text] [Related]

  • 16. Detection of CCNE1/URI (19q12) amplification by in situ hybridisation is common in high grade and type II endometrial cancer.
    Noske A, Brandt S, Valtcheva N, Wagner U, Zhong Q, Bellini E, Fink D, Obermann EC, Moch H, Wild PJ.
    Oncotarget; 2017 Feb 28; 8(9):14794-14805. PubMed ID: 27582547
    [Abstract] [Full Text] [Related]

  • 17. 19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes.
    Aziz D, Etemadmoghadam D, Caldon CE, Au-Yeung G, Deng N, Hutchinson R, Australian Ovarian Cancer Study GroupPeter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia., Bowtell D, Waring P.
    Gynecol Oncol; 2018 Nov 28; 151(2):327-336. PubMed ID: 30209015
    [Abstract] [Full Text] [Related]

  • 18. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.
    Nakayama N, Nakayama K, Shamima Y, Ishikawa M, Katagiri A, Iida K, Miyazaki K.
    Cancer; 2010 Jun 01; 116(11):2621-34. PubMed ID: 20336784
    [Abstract] [Full Text] [Related]

  • 19. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
    Garg K, Levine DA, Olvera N, Dao F, Bisogna M, Secord AA, Berchuck A, Cerami E, Schultz N, Soslow RA.
    Am J Surg Pathol; 2013 Jan 01; 37(1):138-46. PubMed ID: 23232854
    [Abstract] [Full Text] [Related]

  • 20. HtrA1 expression and the prognosis of high-grade serous ovarian carcinoma: a cohort study using digital analysis.
    Gagné A, Têtu B, Orain M, Turcotte S, Plante M, Grégoire J, Renaud MC, Bairati I, Trudel D.
    Diagn Pathol; 2018 Aug 21; 13(1):57. PubMed ID: 30131069
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.